In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.

An immunotherapy research initiative at Vanderbilt University Medical Center is among those being supported by the Mary Kay Foundation, which has announced $1.2 million in funding that will be equally shared among 12 cancer research institutions.

Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.

James Allison, PhD, whose work led to the development of cancer immunotherapies known as “checkpoint inhibitors,” will deliver the next Flexner Discovery Lecture on Thursday, March 8.

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer.

Vanderbilt University cancer researcher Ann Richmond, Ph.D., 2016 recipient of one of the highest honors for scientific achievement bestowed by the U.S. Department of Veterans Affairs, will be a keynote speaker during a national VA research conference next week at Vanderbilt University School of Medicine.